Fate Therapeutics has appointed Jamie Harrell as Senior Vice President of Market Development & Commercial Operations to spearhead the commercialization of its CAR T-cell therapies, including FT819 and FT839, targeting autoimmune diseases like lupus nephritis and rheumatoid arthritis. Harrell brings over 25 years of commercial leadership, with experience launching breakthrough autoimmune treatments and expanding access through outpatient settings. His role will focus on advancing Fate's therapies from clinical trials to market, aiming to broaden patient access in community healthcare settings. This strategic hire supports Fate's goal to transform autoimmune disease treatment with innovative, off-the-shelf cellular immunotherapies.
Fate Therapeutics' strategic leadership update coincides with a mixed performance among health-sector stocks on Pluang. For readers following health stocks, here is Pluang's market snapshot as of Oct 12, 2026 18:11 WIB: out of 128 priced health-sector US stocks, 60 rose and 45 fell. Notable movers include ABCL (AbCellera Biologics Inc) up 1.55% at USD 12.74, NVAX (Novavax Inc) down 1.80% at USD 12.52, and CTXR (Citius Pharmaceuticals Inc) down 1.86% at USD 0.49, with typical hold times ranging from 17 to 59 days on Pluang.
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
A SEON survey of 2,026 U.S. adults reveals that while 68% use AI agents weekly for personal tasks, half are uncomfortable letting AI handle credit card purchases. Only 15% would share financial info with AI, and 43% lack confidence in spotting fraudu...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
Known, a company developing accountability infrastructure for autonomous AI, announced that Edna Conway, former senior security executive at Microsoft and Cisco, has joined its Advisory Council. Conway brings extensive experience in cybersecurity and...
Radiopharm Theranostics announced progress in its oncology radiopharmaceutical pipeline, including preparing for a pivotal Phase 3 imaging trial of RAD101 for recurrent brain metastases after a successful FDA End-of-Phase 2 meeting. The company also ...
